Valoración farmacoeconómica para la elección del tratamiento anti-TNF en Essalud (2017-2022)
Loading...
Código QR
Authors
Herrera Ruíz, Dúber Mariano
Contact Email
Abstract
En Essalud, durante el periodo 2017 – 2022, los pacientes con artritis reumatoidea que fallaban a la terapia convencional podían ser tratados indistintamente con Infliximab o Etanercept, debido a que ambos tratamientos Anti-TNF tienen similar eficacia y seguridad, pero presentaban diferentes costos de tratamiento. Por tanto, el presente trabajo determinó los ahorros que Essalud hubiera podido obtener si los pacientes que recibieron Etanercept hubieran recibido Infliximab, así como también se estimó el número de pacientes adicionales que hubieran podido ser tratados con estos ahorros. Para determinar estos ahorros, se realizó un análisis farmacoeconómico basado en minimización de costos, debido a que ambos tratamientos son bienes perfectamente sustitutos. El resultado de este análisis mostró que Essalud, en el periodo indicado, hubiera obtenido un ahorro aproximado de 105 millones de soles y con ese ahorro beneficiar a13 mil pacientes adicionales.
In Essalud, during the period 2017 – 2022, patients with rheumatoid arthritis who failed conventional therapy could be treated either with Infliximab or Etanercept, because both Anti-TNF treatments have similar efficacy and safety but presented different treatment costs. Therefore, the present work determined the savings that EsSalud could have obtained if the patients who received Etanercept had received Infliximab, as well as estimated the number of additional patients that could have been treated with these savings. To determine these savings, a pharmacoeconomic analysis was carried out based on cost minimization, because both treatments are perfectly substitute goods. The result of this analysis showed that Essalud, in the indicated period, would have obtained an approximate saving of 105 million soles and with that savings benefited 13 thousand additional patients.
In Essalud, during the period 2017 – 2022, patients with rheumatoid arthritis who failed conventional therapy could be treated either with Infliximab or Etanercept, because both Anti-TNF treatments have similar efficacy and safety but presented different treatment costs. Therefore, the present work determined the savings that EsSalud could have obtained if the patients who received Etanercept had received Infliximab, as well as estimated the number of additional patients that could have been treated with these savings. To determine these savings, a pharmacoeconomic analysis was carried out based on cost minimization, because both treatments are perfectly substitute goods. The result of this analysis showed that Essalud, in the indicated period, would have obtained an approximate saving of 105 million soles and with that savings benefited 13 thousand additional patients.
Description
Universidad Nacional Agraria La Molina. Facultad de Economía y Planificación.
Departamento Académico de Economía y Planificación
Keywords
Artritis
Citation
Date
2024
Collections
Seleccionar año de consulta:
Licencia de uso

Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/openAccess